Early detection of nerve damage using the retina

19th January 2015

OCT may be a good way to monitor the efficacy of both immunoprotective and neuroprotective therapies

Exploring the relationship between HIV and MS

19th January 2015

Having HIV, and presumably being on antiretroviral therapy, may reduce the risk of developing MS

New biomarkers to predict progression in MS

19th January 2015

Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS

Natalizumab improves walking in relapsing-remitting MS

19th January 2015

Natalizumab is associated with clinically meaningful improvements in walking speeds

Disease-modifying drugs may reduce disability progression in relapsing-remitting MS

19th January 2015

Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared with historical cohorts

Online cognitive training in Germany

12th January 2015

DMSG’s training programme aims to help people with MS improve cognition functions

MS in focus to move online

12th January 2015

The January 2015 issue of the magazine, which will be about ageing with MS, will be the last in the current format

Working with MS Home in China

12th January 2015

Abdelfatah Ibrahim’s visit focused on supporting a new MS/NMO group

The role deep grey matter in the brain plays in MS

16th December 2014

Deep grey matter is profoundly involved in the disease progression of MS patients

The role of iron and brain damage in MS

16th December 2014

The presence of iron could help us understand the MS inflammation process

Progressive MS and disease-modifying drugs

16th December 2014

Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset of progressive MS

Improving diagnosis of MS

16th December 2014

Over 35 per cent of patients with clinically isolated syndrome were diagnosed earlier when applying the 2010 McDonald Criteria